Femasys stock surged after receiving FDA approval to begin the final phase of its pivotal FemBloc trial, advancing its non-surgical permanent birth control device toward US approval. The company also raised $12 million via convertible notes, with total potential proceeds of $58 million. Retail sentiment turned strongly bullish on the update.